Nicholas Hornstein, Assistant Professor at Northwell Health, shared by Udhayvir Singh Grewal, Resident Physician at Ochsner LSU Health Shreveport, on X:
“Oncology is hard, rare tumor types are harder. I always turn to trusted sources when something atypical makes its way into my clinic. Efforts like this make it easier to tackle these hard topics (and are great examples of mentorship)!
Congrats to Udhayvir Grewal and Charles Shi.”
Quoting Udhayvir Grewal:
“Kudos to Emory Department of Medicine resident Charles Shi
for leading this comprehensive review on systemic therapies in gastroenteropancreatic neuroendocrine carcinomas in the European Journal of Cancer.
GEP-NEC represents an incredibly heterogeneous and challenging disease to treat. Despite years of work, platinum chemotherapy regimens remain the mainstay of treatment (indeed a suboptimal standard of care), with select patients deriving benefit from targeted therapy and immune checkpoint inhibitors.
Luckily there are newer agents (especially DLL3-targeting agents), that are currently in development and appear promising”
Title: Systemic Therapies for Gastroenteropancreatic Neuroendocrine Carcinomas: Current Paradigm and Future Avenues
Authors: Charles W Shi, Aagamjit Singh, Atulya A. Khosla, Rohit Thummalapalli, Sarbajit Mukherjee, Heloisa P Soares, Chandrikha Chandrasekharan, Thorvardur R Halfdanarson, Daniel M Halperin, and Udhayvir S. Grewal
You can also read:EV + P vs Platinum Chemotherapy ± Avelumab Maintenance in Advanced Urothelial Carcinoma
